SCHEMBL2373873

SCHEMBL2373873

[CH2]Oc1cc(OC)c(C=O)c(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.56
LMNA P02545 1/20 0.49
ALDH1A1 P00352 7/20 0.46
PRKDC P78527 1/20 0.42
ABCG2 Q9UNQ0 1/20 0.42
TSHR P16473 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
KDM4E B2RXH2 1/20 0.42
CYP1A1 P04798 3/20 0.42
CYP1B1 Q16678 3/20 0.42
CYP1A2 P05177 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.38
MAOA P21397 2/20 0.37
AOX1 Q06278 1/20 0.36
TRIM24 O15164 1/20 0.36
HPGD P15428 1/20 0.36
ALDH5A1 P51649 1/20 0.36
ABAT P80404 1/20 0.36
TRIM33 Q9UPN9 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2,4,6-Trimethoxybenzaldehyde SCHEMBL34873 0.85 ERN1 (0.74) ERN1LMNAALDH1A1PRKDCABCG2
2,4,6-Trimethoxybenzaldehyde SCHEMBL28687257 0.83 ERN1 (0.71) ERN1LMNAALDH1A1PRKDCABCG2
SCHEMBL3818395 0.83 ERN1 (0.60) ERN1LMNAALDH1A1PRKDCABCG2
2,4,6-Trimethoxybenzaldehyde SCHEMBL28687256 0.81 ERN1 (0.75) ERN1LMNAALDH1A1PRKDCABCG2
SCHEMBL1913197 0.76 LMNA (0.54) ERN1LMNAALDH1A1PRKDCTSHR
SCHEMBL6093598 0.76 ERN1 (0.53) ERN1LMNAALDH1A1PRKDCABCG2
SCHEMBL13362398 0.76 ALDH1A1 (0.59) ERN1LMNAALDH1A1PRKDCTSHR
SCHEMBL415683 0.76 ERN1 (0.57) ERN1LMNAALDH1A1PRKDCTSHR
SCHEMBL439961 0.76 ERN1 (0.52) ERN1LMNAALDH1A1PRKDCTSHR
SCHEMBL3181478 0.75 ALDH1A1 (0.76) LMNAALDH1A1TSHRTDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7749940-B2 Facilitated forward chemical genetics using tagged triazine library NEW YORK UNIVERSITY (US) 2010-07-06 US claimed
WO-2008130944-A1 SOLID PHASE SYNTHESES OF AMINO PYRIMIDINE COMPOUNDS IRM LLC (BM) 2008-10-30 WO claimed
US-6949644-B2 Methods for the synthesis of substituted purines IRM LLC (BM) 2005-09-27 US claimed
EP-1529048-A4 METHODS FOR THE SYNTHESIS OF SUBSTITUTED PURINES IRM LLC (BM) 2005-09-14 EP claimed
EP-1529048-A2 METHODS FOR THE SYNTHESIS OF SUBSTITUTED PURINES IRM LLC (BM) 2005-05-11 EP claimed
US-20030171583-A1 Methods for the synthesis of substituted purines IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) 2003-09-11 US claimed
WO-2003031405-A2 METHODS FOR THE SYNTHESIS OF SUBSTITUTED PURINES IRM LLC (BM) 2003-04-17 WO claimed
EP-4296270-A2 A COMPOSITION COMPRISING STEM CELL CULTURES The Scripps Research Institute (US) 2023-12-27 EP disclosed
EP-3936508-B1 A COMPOSITION COMPRISING STEM CELL CULTURES SCRIPPS RESEARCH INST (US) 2023-12-06 EP disclosed
EP-3936508-A1 A COMPOSITION COMPRISING STEM CELL CULTURES The Scripps Research Institute (US) 2022-01-12 EP disclosed
US-20210403862-A1 METHODS OF ENHANCING CELL SURVIVAL OF STEM CELLS THE SCRIPPS RESEARCH INSTITUTE 2021-12-30 US disclosed
EP-3623374-B1 STEM CELL CULTURES SCRIPPS RESEARCH INST (US) 2021-09-08 EP disclosed
US-10975352-B2 Methods of enhancing cell survival of stem cells THE SCRIPPS RESEARCH INSTITUTE (US) 2021-04-13 US disclosed
EP-1529048-A2 METHODS FOR THE SYNTHESIS OF SUBSTITUTED PURINES IRM LLC (BM) 2005-05-11 EP disclosed
US-20050019831-A1 Facilitated forward chemical genetics using tagged triazine library NEW YORK UNIVERSITY (US) 2005-01-27 US disclosed
WO-2004099106-A2 FACILITATED FORWARD CHEMICAL GENETICS USING TAGGED TRIAZINE LIBRARY NEW YORK UNIVERSITY (US) 2004-11-18 WO disclosed
US-20030191312-A1 Kinase inhibitor scaffolds and methods for their preparation IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) 2003-10-09 US disclosed
US-20030171583-A1 Methods for the synthesis of substituted purines IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) 2003-09-11 US disclosed
WO-2003031405-A2 METHODS FOR THE SYNTHESIS OF SUBSTITUTED PURINES IRM LLC (BM) 2003-04-17 WO disclosed
WO-2003031406-A2 KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION IRM LLC (BM) 2003-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191312-A1 Kinase inhibitor scaffolds and methods for their preparation MAP2K2, MAP2K1, MAP2K7 ERN1 451/4885LMNA 2078/4885ALDH1A1 3304/4885
US-10975352-B2 Methods of enhancing cell survival of stem cells MCL1, BCL2, BCLAF1 ERN1 2309/4885LMNA 656/4885ALDH1A1 429/4885
US-20030171583-A1 Methods for the synthesis of substituted purines PNP, ATIC, NUDT1 ERN1 1691/4885LMNA 1545/4885ALDH1A1 182/4885
US-20210403862-A1 METHODS OF ENHANCING CELL SURVIVAL OF STEM CELLS MCL1, BCL2, BCLAF1 ERN1 2309/4885LMNA 656/4885ALDH1A1 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.